Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.37 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9977538 | 0.84 | POLB (0.51) | HDAC6LMNAPOLBKMT2AMEN1 | |
| SCHEMBL4595797 | 0.79 | TRPV1 (0.54) | NR3C1 | |
| SCHEMBL9977537 | 0.79 | KMT2A (0.50) | HDAC6LMNAPOLBKMT2AMEN1 | |
| SCHEMBL12169725 | 0.78 | CA1 (0.47) | LMNAKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL4606687 | 0.77 | LMNA (0.46) | HDAC6LMNAPOLBKMT2AMEN1 | |
| SCHEMBL4595430 | 0.74 | TRPV1 (0.52) | NR3C1 | |
| SCHEMBL4595576 | 0.72 | MAOB (0.47) | HDAC6LMNAPOLBKMT2AMEN1 | |
| SCHEMBL10278887 | 0.70 | MAOB (0.46) | HDAC6LMNAPOLBKMT2AMEN1 | |
| SCHEMBL4594671 | 0.70 | KMT2A (0.47) | LMNAPOLBKMT2AMEN1GAA | |
| SCHEMBL4623706 | 0.69 | TRPV1 (0.66) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207182-B2 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207182-B2 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207182-B2 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-1874733-B1 | SUBSTITUTED CYCLIC UREA DERIVATIVES AND THE USE THEREOF AS VANILLOID RECEPTOR 1 MODULATORS | GRUENENTHAL GMBH (DE) | 2012-06-20 | — | — | EP | disclosed |
| US-20080090855-A1 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090855-A1 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090855-A1 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090855-A1 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | TRPV1, TRPA1, P2RX3 | HDAC6 1501/4885LMNA 4092/4885POLB 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.